Kindred Biosciences Inc. Daily Stock Analysis

Daily Stock Analysis, KIN, Kindred Biosciences Inc, priceseries

Kindred Biosciences Inc. Daily Stock Analysis
Stock Information
Open
4.94
Close
4.97
High
5.07
Low
4.92
Previous Close
4.93
Daily Price Gain
0.04
YTD High
6.00
YTD High Date
Jan 28, 2021
YTD Low
4.11
YTD Low Date
Mar 4, 2021
YTD Price Change
0.52
YTD Gain
11.69%
52 Week High
6.00
52 Week High Date
Jan 28, 2021
52 Week Low
3.20
52 Week Low Date
Jul 31, 2020
52 Week Price Change
0.73
52 Week Gain
17.22%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 5. 2017
5.30
Jan 31. 2017
6.20
17 Trading Days
17.06%
Link
LONG
Jun 20. 2017
7.05
Jul 10. 2017
8.53
13 Trading Days
20.95%
Link
LONG
Sep 27. 2017
7.60
Oct 18. 2017
8.00
15 Trading Days
5.24%
Link
LONG
Dec 21. 2017
8.35
Jan 8. 2018
8.92
10 Trading Days
6.85%
Link
LONG
Apr 9. 2018
8.60
Apr 23. 2018
9.20
10 Trading Days
6.99%
Link
LONG
Jul 2. 2018
10.90
Aug 7. 2018
13.48
25 Trading Days
23.68%
Link
LONG
Oct 14. 2019
6.99
Nov 11. 2019
8.56
20 Trading Days
22.44%
Link
LONG
Jan 3. 2020
8.82
Jan 17. 2020
9.68
10 Trading Days
9.73%
Link
LONG
Apr 24. 2020
3.99
May 7. 2020
4.68
9 Trading Days
17.34%
Link
LONG
Aug 5. 2020
3.75
Aug 18. 2020
3.96
9 Trading Days
5.59%
Link
LONG
Dec 17. 2020
4.00
Dec 29. 2020
4.20
7 Trading Days
5.07%
Link
LONG
Jan 4. 2021
4.45
Jan 19. 2021
4.72
10 Trading Days
5.99%
Link
Company Information
Stock Symbol
KIN
Exchange
NasdaqCM
Company URL
http://www.kindredbio.com
Company Phone
650-701-7901
CEO
Richard H. Chin
Headquarters
California
Business Address
1555 BAYSHORE HIGHWAY, SUITE 200, BURLINGAME, CA 94010
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001561743
About

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Description

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for the treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs associated with equine metabolic syndrome. It is also developing biologics programs, such as KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) treatment for newborn foals; KIND-502 for the treatment of allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a novel biologics with certain advantages over antibodies, including bispecific binding. The company was founded in 2012 and is headquartered in Burlingame, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading